Laurent Peyrin-Biroulet to Infliximab
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Infliximab.
Connection Strength
3.641
-
Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study. Dig Liver Dis. 2019 01; 51(1):112-119.
Score: 0.533
-
The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018 09; 14(9):739-749.
Score: 0.532
-
Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
Score: 0.499
-
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 06; 23(6):976-985.
Score: 0.488
-
Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"? Dig Dis Sci. 2019 11; 64(11):3035-3037.
Score: 0.144
-
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Aliment Pharmacol Ther. 2018 09; 48(5):574-575.
Score: 0.133
-
Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Dig Liver Dis. 2018 07; 50(7):668-674.
Score: 0.129
-
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018 04; 154(5):1343-1351.e1.
Score: 0.127
-
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis. 2017 11; 23(11):2048-2053.
Score: 0.126
-
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017 Oct; 49(10):1086-1091.
Score: 0.123
-
IBD: To switch or not to switch: that is the biosimilar question. Nat Rev Gastroenterol Hepatol. 2017 09; 14(9):508-509.
Score: 0.123
-
Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):597-606.
Score: 0.121
-
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017 07; 46(2):142-149.
Score: 0.121
-
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. Inflamm Bowel Dis. 2017 01; 23(1):126-132.
Score: 0.119
-
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. Dig Liver Dis. 2017 Mar; 49(3):280-285.
Score: 0.118
-
Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Aliment Pharmacol Ther. 2009 Oct 15; 30(8):854-63.
Score: 0.072
-
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. Curr Med Chem. 2019; 26(2):259-269.
Score: 0.034
-
Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther. 2018 10; 48(8):831-838.
Score: 0.033
-
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. J Crohns Colitis. 2018 Apr 27; 12(5):610-620.
Score: 0.032
-
Infliximab biosimilar CT-P13 for inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2018 06; 3(6):373-375.
Score: 0.032